SUPPLEMENTAL TABLE 1. Effects of torcetrapib on non-fasting concentrations of apoB[a]

Parameter and Study Phase	Torcetrapib Alone		Atorvastatin + Torcetrapib
	120 mg QD (n = 9)	120 mg BID (n = 6)	120 mg QD (n = 9)
Plasma total apoB, mg/dl			
Placebo	98.6 ± 6.1	103.2 ± 7.8	74.6 ± 5.3[h]
Torcetrapib	85.7 ± 4.8[c]	81.5 ± 8.1[c]	62.6 ± 3.6[e,h]
Change (%)	-12 ± 5	-21 ± 5	-15 ± 3
TRL apoB-100, mg/dl			
Placebo	9.5 ± 0.9	9.5 ± 1.4	6.9 ± 0.7[g]
Torcetrapib	6.7 ± 0.5[d]	6.9 ± 0.9[c]	5.2 ± 0.5[d,f]
Change (%)	-23 ± 10	-24 ± 7	-22 ± 8
IDL apoB-100, mg/dl			
Placebo	2.3 ± 0.4	2.7 ± 0.5	1.8 ± 0.2
Torcetrapib	1.4 ± 0.3[b]	0.9 ± 0.1[c]	1.2 ± 0.1[d]
Change (%)	-29 ± 16	-57 ± 14	-29 ± 5
LDL apoB-100, mg/dl			
Placebo	86.8 ± 5.5	91.0 ± 6.4	67.0 ± 5.0[g]
Torcetrapib	77.4 ± 4.5	74.3 ± 7.4[c]	57.1 ± 3.6[d,h]
Change (%)	-9 ± 5	-18 ± 5	-14 ± 3
TRL apoB-48, mg/dl			
Placebo	0.47 ± 0.10	0.57 ± 0.15	0.19 ± 0.04[g]
Torcetrapib	0.23 ± 0.08[d]	0.40 ± 0.12[d]	0.16 ± 0.04
Change (%)	-49 ± 9	-31 ± 6	-2 ± 14

Apo, apolipoprotein; TRL, triglyceride-rich lipoprotein; IDL, intermediate density lipoprotein; QD, once daily; BID, twice daily.

[a]Data are presented as mean ± SEM. Significance for comparison of absolute values with placebo phase was determined using a paired *t*-test, with apoB-48 values being log-transformed before statistical analysis. Significance for comparison between torcetrapib alone and atorvastatin+torcetrapib cohorts during placebo and torcetrapib 120 mg once daily phases was tested by a two-independent sample *t*-test.

[b]$P = 0.05$; [c]$P < 0.05$; [d]$P < 0.01$; [e]$P = 0.001$, for comparison with the placebo phase.

[f]$P = 0.05$; [g]$P < 0.05$; [h]$P < 0.01$, for comparison with the torcetrapib 120 mg QD cohort.

SUPPLEMENTAL TABLE 2. Effects of torcetrapib on non-fasting plasma concentrations of apoA-I and apoA-II[a]

Parameter and Study Phase	Torcetrapib Alone		Atorvastatin + Torcetrapib
	120 mg QD (n = 9)	120 mg BID (n = 6)	120 mg QD (n = 9)
ApoA-I, mg/dl			
Placebo	95.6 ± 3.6	99.6 ± 4.0	85.7 ± 5.3
Torcetrapib	110.3 ± 4.7[d]	131.7 ± 3.1[e]	99.6 ± 7.0[c]
Change (%)	15 ± 2	33 ± 3	16 ± 3
ApoA-II, mg/dl			
Placebo	26.2 ± 1.2	27.6 ± 0.8	24.7 ± 1.4
Torcetrapib	29.3 ± 1.5[d]	33.8 ± 0.6[d]	27.4 ± 1.5[b]
Change (%)	12 ± 2	23 ± 3	11 ± 4

Apo, apolipoprotein; QD, once daily; BID, twice daily.

[a]Data are presented as mean ± SEM. Significance for comparison of absolute values with placebo phase was determined using a paired *t*-test. Significance for comparison between torcetrapib alone and atorvastatin+torcetrapib cohorts during placebo and torcetrapib 120 mg once daily phases was tested by a two-independent sample *t*-test.

[b]$P = 0.01$; [c]$P = 0.001$; [d]$P < 0.001$; [e]$P < 0.0001$, for comparison with the placebo phase.

SUPPLEMENTAL TABLE 3. Effects of torcetrapib on non-fasting concentrations of apoE[a]

Parameter and Study Phase	Torcetrapib Alone		Atorvastatin + Torcetrapib
	120 mg QD (n = 9)	120 mg BID (n = 6)	120 mg QD (n = 9)
Plasma total apoE, mg/dl			
Placebo	6.1 ± 0.7	6.4 ± 0.9	3.8 ± 0.2[f]
Torcetrapib	4.9 ± 0.6	5.4 ± 0.6	4.1 ± 0.4
Change (%)	-18 ± 9	-10 ± 10	8 ± 9
TRL apoE, mg/dl			
Placebo	4.4 ± 0.5	4.6 ± 0.7	2.0 ± 0.3[f]
Torcetrapib	2.9 ± 0.5[c]	3.4 ± 0.5[b]	2.0 ± 0.3
Change (%)	-28 ± 11	-21 ± 8	1 ± 10
IDL apoE, mg/dl			
Placebo	0.18 ± 0.02	0.20 ± 0.03	0.13 ± 0.01
Torcetrapib	0.08 ± 0.02[d]	0.05 ± 0.01[d]	0.06 ± 0.01[e]
Change (%)	-53 ± 12	-73 ± 5	-49 ± 6
LDL apoE, mg/dl			
Placebo	0.15 ± 0.04	0.17 ± 0.07	0.24 ± 0.05
Torcetrapib	0.22 ± 0.08	0.27 ± 0.15	0.25 ± 0.10
Change (%)	170 ± 138	143 ± 139	-8 ± 28
HDL apoE, mg/dl			
Placebo	0.51 ± 0.06	0.57 ± 0.09	0.71 ± 0.13
Torcetrapib	1.05 ± 0.35	1.23 ± 0.42	1.33 ± 0.40
Change (%)	97 ± 47	108 ± 55	84 ± 39

d>1.21 apoE, mg/dl			
Placebo	0.89 ± 0.14	0.91 ± 0.20	0.70 ± 0.12
Torcetrapib	0.60 ± 0.17	0.43 ± 0.10[c]	0.53 ± 0.11
Change (%)	-28 ± 16	-50 ± 10	-22 ± 15
TRL apoE / HDL apoE			
Placebo	9.9 ± 2.3	10.0 ± 3.4	4.6 ± 1.7
Torcetrapib	4.2 ± 0.8[c]	5.7 ± 2.9[d]	2.8 ± 0.8
Change (%)	-49 ± 10	-51 ± 9	-16 ± 23

Apo, apolipoprotein; TRL, triglyceride-rich lipoprotein; IDL, intermediate density lipoprotein; QD, once daily; BID, twice daily.

[a]Data are presented as mean ± SEM. Significance for comparison of absolute values with placebo phase was determined using a paired *t*-test. Significance for comparison between torcetrapib alone and atorvastatin+torcetrapib cohorts during placebo and torcetrapib 120 mg once daily phases was tested by a two-independent sample *t*-test.

[b]$P = 0.05$; [c]$P < 0.05$; [d]$P < 0.01$; [e]$P < 0.001$, for comparison with the placebo phase.

[f]$P < 0.01$, for comparison with the torcetrapib 120 mg QD cohort.

SUPPLEMENTAL TABLE 4. Effects of torcetrapib on the distribution of apoE in lipoprotein particles[a]

Parameter and Study Phase	Torcetrapib Alone		Atorvastatin + Torcetrapib
	120 mg QD (n = 9)	120 mg BID (n = 6)	120 mg QD (n = 9)
TRL particles (%)			
Placebo	70.0 ± 2.9	70.3 ± 3.6	52.5 ± 6.3[e]
Torcetrapib	60.5 ± 5.2	64.2 ± 8.1	50.3 ± 7.6
Change (%)	-12 ± 8	-9 ± 10	-3 ± 11
IDL particles (%)			
Placebo	3.0 ± 0.4	3.0 ± 0.4	3.4 ± 0.4
Torcetrapib	1.6 ± 0.4[c]	0.9 ± 0.1[d]	1.7 ± 0.4[d]
Change (%)	-42 ± 15	-70 ± 5	-51 ± 7
LDL particles (%)			
Placebo	2.8 ± 1.0	2.5 ± 0.8	6.4 ± 1.3[e]
Torcetrapib	5.0 ± 1.4	4.7 ± 2.1	5.3 ± 1.4
Change (%)	329 ± 255	137 ± 123	-22 ± 18
HDL particles (%)			
Placebo	9.4 ± 1.5	9.8 ± 2.0	18.8 ± 3.0[e]
Torcetrapib	21.0 ± 5.2[b]	22.4 ± 5.5[c]	28.8 ± 5.8
Change (%)	143 ± 52	123 ± 42	67 ± 26
d>1.21 plasma (%)			
Placebo	14.7 ± 1.4	14.4 ± 2.2	18.9 ± 3.0
Torcetrapib	11.9 ± 1.9	8.5 ± 0.7[c]	14.2 ± 3.9
Change (%)	-13 ± 16	-36 ± 7	-27 ± 14

TRL, triglyceride-rich lipoprotein; IDL, intermediate density lipoprotein; QD, once daily; BID, twice daily.

[a]Data are presented as mean ± SEM. Significance for comparison of absolute values with placebo phase was determined using a paired *t*-test. Significance for comparison between torcetrapib alone and atorvastatin+torcetrapib cohorts during placebo and torcetrapib 120 mg once daily phases was tested by a two-independent sample *t*-test.

[b]$P = 0.05$; [c]$P < 0.05$; [d]$P < 0.01$, for comparison with the placebo phase.

[e]$P < 0.05$, for comparison with the torcetrapib 120 mg QD cohort.

SUPPLEMENTAL TABLE 5. Effects of torcetrapib on TRL composition[a]

Parameter and Study Phase	Torcetrapib Alone		Atorvastatin + Torcetrapib
	120 mg QD (n = 9)	120 mg BID (n = 6)	120 mg QD (n = 9)
Total cholesterol, mg/dl			
Placebo	32.5 ± 3.7	35.1 ± 5.7	17.3 ± 2.3[g]
Torcetrapib	17.0 ± 2.2[e]	20.4 ± 4.6[d]	9.8 ± 1.6[d,f]
Change (%)	-43 ± 8	-41 ± 7	-41 ± 8
Free cholesterol, mg/dl			
Placebo	16.6 ± 1.7	17.5 ± 2.5	9.7 ± 1.3[g]
Torcetrapib	12.9 ± 1.6[b]	16.2 ± 3.4	7.7 ± 1.4[f]
Change (%)	-17 ± 11	-8 ± 9	-18 ± 11
Cholesteryl ester, mg/dl			
Placebo	26.8 ± 3.4	29.6 ± 5.4	12.7 ± 1.7[g]
Torcetrapib	6.9 ± 1.2[e]	7.0 ± 2.4[d]	3.5 ± 0.4[d,f]
Change (%)	-73 ± 3	-78 ± 5	-69 ± 4
Triglycerides, mg/dl			
Placebo	202.2 ± 24.4	207.8 ± 32.3	123.4 ± 19.8[f]
Torcetrapib	159.6 ± 23.2	199.8 ± 44.7	102.6 ± 20.0[f]
Change (%)	-17 ± 10	-6 ± 9	-16 ± 12
Phospholipid, mg/dl			
Placebo	52.2 ± 6.1	52.2 ± 7.8	29.9 ± 4.3[g]
Torcetrapib	34.9 ± 4.7[d]	40.7 ± 8.4[c]	21.4 ± 3.9[c,f]
Change (%)	-28 ± 9	-22 ± 7	-27 ± 10

Protein, mg/dl			
Placebo	67.6 ± 4.2	64.4 ± 5.5	68.0 ± 5.0
Torcetrapib	58.7 ± 5.8	53.6 ± 5.7[c]	61.0 ± 7.8
Change (%)	-13 ± 6	-16 ± 5	-13 ± 5

TRL, triglyceride-rich lipoprotein; QD, once daily; BID, twice daily.

[a]Data are presented as mean ± SEM. Significance for comparison of absolute values with placebo phase was determined using a paired *t*-test, with triglycerides being log-transformed before statistical analysis. Significance for comparison between torcetrapib alone and atorvastatin+torcetrapib cohorts during placebo and torcetrapib 120 mg once daily phases was tested by a two-independent sample *t*-test.

[b]$P = 0.05$; [c]$P < 0.05$; [d]$P < 0.01$; [e]$P < 0.001$, for comparison with the placebo phase.

[f]$P < 0.05$; [g]$P < 0.01$, for comparison with the torcetrapib 120 mg QD cohort.

SUPPLEMENTAL TABLE 6. Effects of torcetrapib on IDL composition[a]

Parameter and Study Phase	Torcetrapib Alone		Atorvastatin + Torcetrapib
	120 mg QD (n = 8)	120 mg BID (n = 6)	120 mg QD (n = 7)
Total cholesterol, mg/dl			
Placebo	6.1 ± 1.3	7.2 ± 1.6	3.3 ± 0.5
Torcetrapib	2.4 ± 0.4[b]	1.8 ± 0.1[b]	1.7 ± 0.1[b]
Change (%)	-50 ± 10	-66 ± 9	-41 ± 7
Free cholesterol, mg/dl			
Placebo	2.0 ± 0.3	2.3 ± 0.4	1.3 ± 0.2
Torcetrapib	0.9 ± 0.1[b]	0.6 ± 0.1[c]	0.7 ± 0.1[b]
Change (%)	-45 ± 10	-71 ± 5	-43 ± 6
Cholesteryl ester, mg/dl			
Placebo	6.8 ± 1.7	8.2 ± 2.0	2.5 ± 0.7[d]
Torcetrapib	2.4 ± 0.6[b]	2.0 ± 0.2[b]	1.3 ± 0.3[b]
Change (%)	-56 ± 9	-60 ± 16	-39 ± 11
Triglycerides, mg/dl			
Placebo	13.8 ± 1.0	14.6 ± 1.0	14.2 ± 1.1
Torcetrapib	14.6 ± 2.8	12.1 ± 0.9	12.4 ± 1.2
Change (%)	10 ± 26	-15 ± 10	-11 ± 8
Phospholipid, mg/dl			
Placebo	4.8 ± 0.9	5.4 ± 1.2	2.4 ± 0.3[d]
Torcetrapib	2.1 ± 0.4[b]	1.6 ± 0.4[b]	1.3 ± 0.2[c]
Change (%)	-46 ± 13	-53 ± 19	-47 ± 8

Protein, mg/dl			
Placebo	20.0 ± 3.9	16.5 ± 1.5	35.6 ± 5.3[d]
Torcetrapib	18.4 ± 4.9	12.7 ± 1.0[b]	33.8 ± 5.5[d]
Change (%)	-11 ± 7	-21 ± 6	-6 ± 3

IDL, intermediate density lipoprotein; QD, once daily; BID, twice daily.

[a]Data are presented as mean ± SEM. Significance for comparison of absolute values with placebo phase was determined using a paired *t*-test, with triglycerides being log-transformed before statistical analysis. Significance for comparison between torcetrapib alone and atorvastatin+torcetrapib cohorts during placebo and torcetrapib 120 mg once daily phases was tested by a two-independent sample *t*-test.

[b]$P < 0.05$; [c]$P < 0.01$, for comparison with the placebo phase.

[d]$P < 0.05$, for comparison with the torcetrapib 120 mg QD cohort.

SUPPLEMENTAL TABLE 7. Effects of torcetrapib on LDL composition[a]

Parameter and Study Phase	Torcetrapib Alone		Atorvastatin + Torcetrapib
	120 mg QD (n = 8)	120 mg BID (n = 6)	120 mg QD (n = 9)
Total cholesterol, mg/dl			
Placebo	72.0 ± 7.4	78.6 ± 7.4	62.8 ± 9.0
Torcetrapib	68.5 ± 5.0	58.8 ± 6.9[c]	46.7 ± 5.3[c,f]
Change (%)	0 ± 9	-24 ± 8	-22 ± 5
Free cholesterol, mg/dl			
Placebo	20.0 ± 2.2	21.4 ± 2.1	17.0 ± 2.4
Torcetrapib	17.9 ± 1.4	15.9 ± 1.6	13.3 ± 1.4[c,e]
Change (%)	-6 ± 7	-23 ± 9	-17 ± 6
Cholesteryl ester, mg/dl			
Placebo	87.3 ± 9.1	96.0 ± 9.7	77.0 ± 11.1
Torcetrapib	84.9 ± 6.1	74.9 ± 9.8[c]	56.1 ± 6.6[d,f]
Change (%)	2 ± 9	-21 ± 7	-24 ± 5
Triglycerides, mg/dl			
Placebo	21.2 ± 1.5	24.0 ± 1.8	22.1 ± 1.7
Torcetrapib	20.6 ± 3.1	17.6 ± 1.8[b]	20.9 ± 2.8
Change (%)	-3 ± 13	-25 ± 11	-5 ± 10
Phospholipid, mg/dl			
Placebo	48.0 ± 4.9	50.4 ± 4.8	41.5 ± 5.8
Torcetrapib	42.5 ± 2.9	39.8 ± 4.0	31.3 ± 3.3[d,e]
Change (%)	-8 ± 8	-18 ± 9	-21 ± 4

Protein, mg/dl			
Placebo	120.0 ± 4.7	123.6 ± 5.3	86.9 ± 6.7[f]
Torcetrapib	106.0 ± 4.3[d]	106.6 ± 5.9[c]	73.5 ± 5.8[d,g]
Change (%)	-12 ± 2	-14 ± 4	-15 ± 3

QD, once daily; BID, twice daily.

[a]Data are presented as mean ± SEM. Significance for comparison of absolute values with placebo phase was determined using a paired *t*-test, with triglycerides being log-transformed before statistical analysis. Significance for comparison between torcetrapib alone and atorvastatin+torcetrapib cohorts during placebo and torcetrapib 120 mg once daily phases was tested by a two-independent sample *t*-test.

[b]$P = 0.05$; [c]$P < 0.05$; [d]$P < 0.01$, for comparison with the placebo phase.

[e]$P < 0.05$; [f]$P < 0.01$; [g]$P < 0.001$, for comparison with the torcetrapib 120 mg QD cohort.

SUPPLEMENTAL TABLE 8. Effects of torcetrapib on HDL composition[a]

Parameter and Study Phase	Torcetrapib Alone		Atorvastatin + Torcetrapib
	120 mg QD (n = 9)	120 mg BID (n = 6)	120 mg QD (n = 9)
Total cholesterol, mg/dl			
Placebo	20.1 ± 1.8	21.3 ± 1.4	22.1 ± 1.0
Torcetrapib	32.2 ± 3.0[d]	46.3 ± 3.4[d]	33.4 ± 1.6[d]
Change (%)	63 ± 10	119 ± 12	53 ± 9
Free cholesterol, mg/dl			
Placebo	4.6 ± 0.5	4.6 ± 0.5	5.3 ± 0.3
Torcetrapib	6.5 ± 0.7[c]	9.4 ± 1.1[d]	7.4 ± 0.6[b]
Change (%)	40 ± 8	106 ± 14	44 ± 14
Cholesteryl ester, mg/dl			
Placebo	26.0 ± 2.3	28.0 ± 1.8	28.2 ± 1.3
Torcetrapib	43.2 ± 3.9[d]	62.0 ± 4.1[d]	43.6 ± 2.3[d]
Change (%)	72 ± 14	123 ± 14	56 ± 9
Triglycerides, mg/dl			
Placebo	21.8 ± 1.6	18.9 ± 0.7	17.0 ± 1.5[e]
Torcetrapib	13.3 ± 1.1[c]	15.1 ± 1.6	14.7 ± 1.8
Change (%)	-36 ± 7	-20 ± 9	-8 ± 13
Phospholipid, mg/dl			
Placebo	38.6 ± 2.1	39.4 ± 1.9	40.8 ± 0.9
Torcetrapib	52.2 ± 3.5[c]	74.2 ± 4.5[d]	53.5 ± 2.0[d]
Change (%)	36 ± 8	88 ± 7	32 ± 6

Protein, mg/dl			
Placebo	141.2 ± 3.2	144.1 ± 3.6	139.4 ± 4.9
Torcetrapib	161.6 ± 8.6[b]	204.4 ± 13.8[c]	153.5 ± 8.5
Change (%)	14 ± 6	42 ± 11	10 ± 6

QD, once daily; BID, twice daily.

[a]Data are presented as mean ± SEM. Significance for comparison of absolute values with placebo phase was determined using a paired *t*-test, with triglycerides being log-transformed before statistical analysis. Significance for comparison between torcetrapib alone and atorvastatin+torcetrapib cohorts during placebo and torcetrapib 120 mg once daily phases was tested by a two-independent sample *t*-test.

[b]$P < 0.05$; [c]$P < 0.01$; [d]$P < 0.001$, for comparison with the placebo phase.

[e]$P < 0.05$, for comparison with the torcetrapib 120 mg QD cohort.

SUPPLEMENTAL TABLE 9. Effects of torcetrapib on precursors of bile acid and cholesterol synthesis and fecal bile acid and neutral sterol content[a]

	Torcetrapib Alone		Atorvastatin + Torcetrapib
Parameter and Study Phase	120 mg QD (n = 10)[b]	120 mg BID (n = 6)	120 mg QD (n = 9)
Serum 7α-hydroxy-4-cholesten-3-one, ng/ml			
Placebo	38 ± 29	29 ± 18	23 ± 20
Torcetrapib	36 ± 27	38 ± 22	22 ± 13
Change (%)	17 ± 52	35 ± 49	16 ± 66
Serum lathosterol, μg/ml			
Placebo	2.0 ± 0.8	1.7 ± 0.5	0.6 ± 0.3[f]
Torcetrapib	2.4 ± 0.9	2.3 ± 1.0	0.5 ± 0.2[f]
Change (%)	16 ± 20	32 ± 43	-18 ± 28
Fecal bile acids, mg/mg plant sterols			
Placebo	2.4 ± 1.5	1.9 ± 0.7	1.4 ± 0.4
Torcetrapib	2.2 ± 1.2	2.2 ± 1.1	1.2 ± 0.4[c,d]
Change (%)	4 ± 50	13 ± 46	-16 ± 20
Fecal neutral sterols, mg/mg plant sterols			
Placebo	3.3 ± 1.0	2.9 ± 0.5	1.9 ± 0.7[e]
Torcetrapib	3.3 ± 0.6	2.9 ± 1.0	1.7 ± 0.4[f]
Change (%)	5 ± 28	-1 ± 32	-8 ± 22

QD, once daily; BID, twice daily.

[a]Data are presented as mean ± SD. Significance for comparison of absolute values with placebo phase was determined using a paired *t*-test. Significance for comparison between torcetrapib

alone and atorvastatin+torcetrapib cohorts during placebo and torcetrapib 120 mg once daily phases was tested by a two-independent sample *t*-test.

[b]Torcetrapib alone 120 mg QD cohort includes subject with unsatisfactory apoB kinetic data (see Methods).

[c]$P < 0.04$, for comparison with the placebo phase.

[d]$P < 0.05$; [e]$P < 0.01$; [f]$P < 0.0001$, for comparison with torcetrapib 102 mg QD cohort.